{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:37:05Z","timestamp":1789699025801,"version":"4.0.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T00:00:00Z","timestamp":1562889600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T00:00:00Z","timestamp":1562889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005754","name":"Sahlgrenska Universitetssjukhuset","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005754","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12957-019-1663-z","type":"journal-article","created":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T15:02:33Z","timestamp":1562943753000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Surgery for gastrointestinal metastases of malignant melanoma \u2014 a retrospective exploratory study"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3512-4535","authenticated-orcid":false,"given":"Carl Jacob","family":"Holmberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulan","family":"Alwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Ny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Olofsson Bagge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Katsarelias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,12]]},"reference":[{"key":"1663_CR1","unstructured":"Matthews NH, L.W., Qureshi AA, et al., Epidemiology of melanoma. In: Ward WH, Farma JM, editors. Cutaneous melanoma: etiology and therapy [Internet]. 2017, Brisbane (AU): Codon Publications."},{"issue":"6","key":"1663_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"1663_CR3","unstructured":"Cancerincidens i Sverige 2017, Nya diagnostiserade cancerfall \u00e5r 2017, Sveriges officiella statistik, Socialstyrelsen. [Cancer incidens in Sweden 2017, New diagnosed cancer cases in 2017, Sweden\u2019s official statistics, The National Board of Health and Welfare in Sweden]. 2018."},{"issue":"6","key":"1663_CR4","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.21409","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald JE, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472\u201392.","journal-title":"CA Cancer J Clin"},{"key":"1663_CR5","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/archsurg.1964.01310240065013","volume":"88","author":"TK Dasgupta","year":"1964","unstructured":"Dasgupta TK, Brasfield RD. Metastatic melanoma of the gastrointestinal tract. Arch Surg. 1964;88:969\u201373.","journal-title":"Arch Surg"},{"issue":"9","key":"1663_CR6","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1001\/archsurg.1996.01430210073013","volume":"131","author":"DW Ollila","year":"1996","unstructured":"Ollila DW, et al. Surgical resection for melanoma metastatic to the gastrointestinal tract. Archives of Surgery. 1996;131(9):975\u201380.","journal-title":"Archives of Surgery"},{"issue":"7","key":"1663_CR7","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1001\/jamasurg.2017.0459","volume":"152","author":"GB Deutsch","year":"2017","unstructured":"Deutsch GB, et al. Association of surgical treatment, systemic therapy, and survival in patients with abdominal visceral melanoma metastases, 1965-2014: Relevance of Surgical Cure in the Era of Modern Systemic Therapy. JAMA Surg. 2017;152(7):672\u20138.","journal-title":"JAMA Surg"},{"issue":"8","key":"1663_CR8","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1002\/jso.23938","volume":"111","author":"M He","year":"2015","unstructured":"He M, et al. Post-operative survival following metastasectomy for patients receiving BRAF inhibitor therapy is associated with duration of pre-operative treatment and elective indication. J Surg Oncol. 2015;111(8):980\u20134.","journal-title":"J Surg Oncol"},{"issue":"6","key":"1663_CR9","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.21873\/anticanres.12650","volume":"38","author":"D Mantas","year":"2018","unstructured":"Mantas D, et al. Abdominal emergencies in patients with stage IV melanoma: the role of surgery: a single-centre experience. Anticancer Res. 2018;38(6):3713\u20138.","journal-title":"Anticancer Res"},{"issue":"26","key":"1663_CR10","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Eng J Med. 2011;364(26):2507\u201316.","journal-title":"N Eng J Med"},{"issue":"18","key":"1663_CR11","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Eng J Med. 2012;367(18):1694\u2013703.","journal-title":"N Eng J Med"},{"issue":"2","key":"1663_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1203421","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Eng J Med. 2012;367(2):107\u201314.","journal-title":"N Eng J Med"},{"issue":"8","key":"1663_CR13","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Eng J Med. 2010;363(8):711\u201323.","journal-title":"N Eng J Med"},{"issue":"2","key":"1663_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205\u201313.","journal-title":"Ann Surg"},{"key":"1663_CR15","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ijsu.2017.08.586","volume":"46","author":"RA Agha","year":"2017","unstructured":"Agha RA, et al. The STROCSS statement: strengthening the reporting of cohort studies in surgery. Int J Surg. 2017;46:198\u2013202.","journal-title":"Int J Surg"},{"issue":"15_suppl","key":"1663_CR16","doi-asserted-by":"publisher","first-page":"e21566","DOI":"10.1200\/JCO.2018.36.15_suppl.e21566","volume":"36","author":"L Ny","year":"2018","unstructured":"Ny L, et al. BRAF mutation as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis. J Clin Oncol. 2018;36(15_suppl):e21566.","journal-title":"J Clin Oncol"},{"issue":"20","key":"1663_CR17","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1002\/cncr.26111","volume":"117","author":"JA Sosman","year":"2011","unstructured":"Sosman JA, et al. A phase II trial of complete resection for stage IV melanoma: results of Southwest Oncology Group (SWOG) Clinical Trial S9430. Cancer. 2011;117(20):4740\u201306.","journal-title":"Cancer"},{"key":"1663_CR18","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3389\/fonc.2018.00202","volume":"8","author":"H Helgadottir","year":"2018","unstructured":"Helgadottir H, Drakensj\u00f6 IRT, Girnita A. Personalized medicine in malignant melanoma: towards patient tailored treatment. Front Oncol. 2018;8:202.","journal-title":"Front Oncol"},{"issue":"1","key":"1663_CR19","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41467-017-00786-z","volume":"8","author":"H Jespersen","year":"2017","unstructured":"Jespersen H, et al. Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model. Nat Commun. 2017;8(1):707.","journal-title":"Nat Commun"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-019-1663-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12957-019-1663-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-019-1663-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T23:09:40Z","timestamp":1594422580000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-019-1663-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,12]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1663"],"URL":"https:\/\/doi.org\/10.1186\/s12957-019-1663-z","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,12]]},"assertion":[{"value":"2 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the regional ethical review board in Gothenburg, Sweden (Dnr 949-18).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ROB has received research grants from Astra Zeneca and speaker honorarium from Roche and Pfizer and has served on advisory boards for Amgen, BMS, and MSD.LN has received research grants (Inst) from MSD and Syndax Pharmaceuticals and speaker honorarium from AstraZeneca, BMS, and MSD and has served on advisory boards for BMS, MSD, Novartis, and Pierre Fabre. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"123"}}